Observational Secondary Data Study describing Treatment with Dapagliflozin among adult Chronic Kidney Disease Patients

Trial Identifier: D169AR00025
Sponsor: AstraZeneca
NCTID:: NCT06203704
Start Date: December 2023
Primary Completion Date: September 2025
Study Completion Date: September 2025
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Bulgaria Plovdiv, Bulgaria
Bulgaria Sofia, Bulgaria
Bulgaria Varna, Bulgaria
Croatia Zagreb, Croatia
Hungary Bekescsaba, Hungary
Hungary Budapest, Hungary
Hungary Debrecen, Hungary
Hungary Godollo, Hungary
Hungary Karcag, Hungary
Hungary Kecskemet, Hungary
Hungary Miskolc, Hungary
Hungary Nagykanizsa, Hungary
Hungary Nyiregyhaza, Hungary
Hungary Pecs, Hungary
Hungary Siofok, Hungary
Hungary Szeged, Hungary
Hungary Szombathely, Hungary
Hungary Veszprem, Hungary
Poland Bialystok, Poland
Poland Boleslawiec, Poland
Poland Bydgoszcz, Poland
Poland Choszczno, Poland
Poland Chrzanow, Poland
Poland Katowice, Poland
Poland Krakow, Poland
Poland Lodz, Poland
Poland Olsztyn, Poland
Poland Opole, Poland
Poland Sieradz, Poland
Poland Sroda Wielkopolska, Poland
Poland Szczecin, Poland
Poland Warszawa, Poland
Poland Wegrow, Poland
Poland Wroclaw, Poland
Poland Zielona Gora, Poland
Poland Zywiec, Poland
Romania Bistrita, Romania
Romania Bucharest, Romania
Romania Bucuresti, Romania
Romania Cluj-Napoca, Romania
Romania Galati, Romania
Romania Iasi, Romania
Romania Oradea, Romania
Romania Resita, Romania
Romania Satu Mare, Romania
Romania Targu-Mures, Romania
Romania Timisoara, Romania
Serbia Belgrade, Serbia
Slovenia Brezice, Slovenia
Slovenia Cerknica, Slovenia
Slovenia Menges, Slovenia
Slovenia Portoroz, Slovenia
Slovenia Ptuj, Slovenia
Slovenia Radlje ob Dravi, Slovenia
Slovenia Ruse, Slovenia
Slovenia Sevnica, Slovenia
Slovenia Skofja Loka, Slovenia
Slovenia Zagorje, Slovenia